News Major UK market breakthrough for Keytruda in lung cancer But funding will last only two years on CDF.
Views & Analysis The UK general election: what pharma wants As the UK election approaches how do the main parties measure up regarding health funding?
News Labour's tax rises could damage economy, says UK pharma Corporation tax increase could damage UK's competitiveness, says ABPI
Views & Analysis Partnerships can drive more early-stage assets into clinical... Investors who see early-stage compounds and indications as valuable assets can support them to market.
Views & Analysis Novartis: UK market access starting to resemble austerity-hi... The new head of Novartis UK thinks the country has gone backwards in terms of access to medicines.
Views & Analysis Pharmacovigilance as a business enabler Industry may be limiting its options if safety takes a back seat to efficacy in trial design and product development.
News Beacon's XLRP gene therapy set for filing after phase 3 win Beacon is preparing to file for approval of its gene therapy for X-linked retinitis pigmentosa, after reporting encouraging phase 3 data.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
